Nebivolol Teva (Nebivolol)

Nebivolol selectively blocks β1‑adrenergic receptors in the heart, decreasing heart rate and contractility. It also stimulates endothelial nitric‑oxide release, causing vasodilation. The combined actions lower peripheral resistance and arterial pressure.

The exact dose of Nebivolol Teva is determined by the prescribing clinician based on the patient’s condition, response, and any comorbidities. Dosage may be adjusted during treatment to achieve optimal blood‑pressure control or heart‑failure management.

Safety data for nebivolol in pregnancy and lactation are limited, and the product’s pregnancy category is listed as unknown. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and under close medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nebivolol is a β1‑selective blocker with additional nitric‑oxide‑mediated vasodilation, which may result in fewer metabolic side effects compared with non‑selective beta‑blockers. Its dual mechanism can offer better blood‑pressure control while preserving endothelial function.

Nebivolol Teva tablets should be stored at room temperature, below 25 °C, in the original packaging. Keep the container tightly closed and protect it from moisture and direct sunlight to maintain product stability.

Nebivolol Teva is taken orally, usually once daily with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare professional.

Serious risks include severe bradycardia, marked hypotension, heart block, bronchospasm in patients with reactive airway disease, and rare allergic reactions such as angioedema. Patients should seek immediate medical attention if they experience these symptoms.

Nebivolol is contraindicated in patients with known hypersensitivity to nebivolol or any excipients, in those with severe bradycardia, second‑ or third‑degree AV block without a pacemaker, and in patients with uncompensated heart failure. Caution is also advised for individuals with asthma or severe chronic obstructive pulmonary disease.